These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22009379)

  • 1. Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?
    Moghbel MC; Saboury B; Basu S; Metzler SD; Torigian DA; Långström B; Alavi A
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):202-8. PubMed ID: 22009379
    [No Abstract]   [Full Text] [Related]  

  • 2. [Amyloid-plaque imaging of the brain using PET].
    Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
    Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers.
    Morbelli S; Bauckneht M
    Methods Mol Biol; 2018; 1750():203-212. PubMed ID: 29512074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.
    Villemagne VL; Klunk WE; Mathis CA; Rowe CC; Brooks DJ; Hyman BT; Ikonomovic MD; Ishii K; Jack CR; Jagust WJ; Johnson KA; Koeppe RA; Lowe VJ; Masters CL; Montine TJ; Morris JC; Nordberg A; Petersen RC; Reiman EM; Selkoe DJ; Sperling RA; Van Laere K; Weiner MW; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39(2):209-19. PubMed ID: 22218879
    [No Abstract]   [Full Text] [Related]  

  • 5. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET.
    Okamura N; Furumoto S; Fodero-Tavoletti MT; Mulligan RS; Harada R; Yates P; Pejoska S; Kudo Y; Masters CL; Yanai K; Rowe CC; Villemagne VL
    Brain; 2014 Jun; 137(Pt 6):1762-71. PubMed ID: 24681664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI.
    Huddleston DE; Small SA
    Nat Clin Pract Neurol; 2005 Dec; 1(2):96-105. PubMed ID: 16932505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid imaging using high-field magnetic resonance.
    Amatsubo T; Yanagisawa D; Morikawa S; Taguchi H; Tooyama I
    Magn Reson Med Sci; 2010; 9(3):95-9. PubMed ID: 20885081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a PET/SPECT agent for amyloid imaging in Alzheimer's disease.
    Wang Y; Klunk WE; Debnath ML; Huang GF; Holt DP; Shao L; Mathis CA
    J Mol Neurosci; 2004; 24(1):55-62. PubMed ID: 15314250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
    Timmers T; van Berckel BNM; Lammertsma AA; Ossenkoppele R
    Methods Mol Biol; 2018; 1750():221-229. PubMed ID: 29512076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta amyloid imaging with positron emission tomography (PET) for evaluation of suspected Alzheimer's disease or other causes of cognitive decline.
    Technol Eval Cent Assess Program Exec Summ; 2013 Feb; 27(5):1-4. PubMed ID: 23589929
    [No Abstract]   [Full Text] [Related]  

  • 13. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis optimization of 2-(4-N-[11C]methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB), β-amyloid PET imaging tracer for Alzheimer's disease diagnosis.
    Coliva A; Monterisi C; Apollaro A; Gatti D; Penso M; Gianolli L; Perani D; Gilardi MC; Carpinelli A
    Appl Radiat Isot; 2015 Nov; 105():66-71. PubMed ID: 26248085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.
    Kung HF; Choi SR; Qu W; Zhang W; Skovronsky D
    J Med Chem; 2010 Feb; 53(3):933-41. PubMed ID: 19845387
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand.
    Juréus A; Swahn BM; Sandell J; Jeppsson F; Johnson AE; Johnström P; Neelissen JA; Sunnemark D; Farde L; Svensson SP
    J Neurochem; 2010 Aug; 114(3):784-94. PubMed ID: 20477945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review.
    Tu P; Fu H; Cui M
    Expert Opin Ther Pat; 2015 Apr; 25(4):413-23. PubMed ID: 25746836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer's disease and healthy volunteers.
    Tiepolt S; Barthel H; Butzke D; Hesse S; Patt M; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):238-44. PubMed ID: 23104671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The contribution of nuclear medicine procedures in the diagnosis of dementia of Alzheimer's type. Imaging beta amyloid plaques].
    Tsolaki M; Trontzos C; Kazis A
    Hell J Nucl Med; 2005; 8(3):187-90. PubMed ID: 16390030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.